Finding 1: Ketamine has a unique property in comparison to other non-competitive NMDAR antagonists: it’s long-lasting effect.
* They measured the reduction of immobility in rats undergoing a forced-swim test after being treated with three different NMDA antagonists: ketamine, CPP, and MK-801. They compared the effects various times after injection: 30 mins, 3 hrs, 24 hrs, and a week.
\
Finding 2: BDNF KO occlude’s ketamine’s effect, meaning BDNF is essential for Ketamine’s action
* When *BDNF* was knocked out, there was not a strong reduced immobility response to ketamine 30 ins or 24 hours after injection (but there was in the control group).
\
Finding 3: Ketamine works as an antidepressant by prompting eEF2 de-phosphorylation which promotes BDMF synthesis
* injected cells with **rottlerin** which prompts eEF2 de-phosphorylation and noted increased BDNF expression, decreased phosphorylation and decreased immobility
* Everyone agrees with this
\
__Against Zanos-Zarate et al.)__
\*Finding 4: Ketamine’s primary action is via Ketamine at NMDARs
* Miller would agree
\
\*Finding 5: Like ketamine, HNK works as an antagonist of NMDARs
* He recorded spontaneous excitations (current flow) through NMDARs and compared the effect NMDAR antagonists have on them -- including ketamine. He found that at high enough concentrations, HNK greatly reduced NMDA current flow just like the other NMDAR antagonists.
\
\
Finding ?: AMPAR changes in the hippocampus, not the prefrontal cortex (supported by Zarate)